Abstracts tagged "Comorbidity"

Abstract Number: 2029 • 2014 ACR/ARHP Annual Meeting
Treatment Patterns of Multimorbid Rheumatoid Arthritis Patients: Results from an International Cross-Sectional Study
Helga Radner^1,2, Kazuki Yoshida^3,4, Ihsane Hmamouchi⁵, Maxime Dougados^6,7, Josef Smolen⁸ and Daniel H Solomon⁹, ¹Department of Internal Medicine III; Division of Rheumatology, Medical University Vienna, Vienna, Austria, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ³Department of Rheumatology, Kameda Medical Center, Kamogawa, Japan, Kamogawa, Japan, ⁴Division of Rheumatology, Brigham and Women’s Hospital, Boston, MA, ⁵Biostatistics, Epidemiology LBRCE, Mohamed V Souissi University, Rabat, Morocco, ⁶Descartes University, Cochin Hospital, Paris, France, ⁷INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France., Paris, France, ⁸Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁹Rheumatology, Brigham and Women's Hospital, Boston, MA
Treatment Patterns of Multimorbid Rheumatoid Arthritis Patients: Results from an International Cross-sectional StudyBackground/Purpose The presence of multimorbidity could lead to less intensive treatment of RA.…
Abstract Number: 1771 • 2014 ACR/ARHP Annual Meeting
Arterial Thrombotic Events in Systemic Vasculitis
Alexander Tsoukas¹, Sasha Bernatsky², Lawrence Joseph³, David Buckeridge⁴, Patrick Belisle⁵ and Christian A. Pineau¹, ¹Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ²Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ³McGill University, Montreal, QC, Canada, ⁴Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada, ⁵Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose To estimate the incidence rate of clinically apparent arterial thrombotic events and associated comorbidities in patients with primary systemic vasculitis. Methods Using large-cohort administrative…
Abstract Number: 1570 • 2014 ACR/ARHP Annual Meeting
Relationship Between Psoriatic Arthritis Severity, Duration, and Comorbidities
Stacy Tanner¹, Molly McFadden², Daniel Clegg³ and Jessica Walsh⁴, ¹Internal Medicine, University of Utah, Salt Lake City, UT, ²Internal Medicine-Division of Epidemiology, University of Utah, SLC, UT, ³Division of Rheumatology, University of Utah Medical Ctr, Salt Lake City, UT, ⁴Rheumatology Room 4B200 School of Medicine, University of Utah, Salt Lake City, UT
Background/Purpose People with psoriatic arthritis (PsA) have an increased risk for several comorbidities that negatively impact quality of life and survival. Defining the relationships between…
Abstract Number: 1279 • 2014 ACR/ARHP Annual Meeting
Pre-Operative Musculoskeletal Comorbidities Limit Improvement in Functional Outcomes and Hip Pain in Total Hip Arthroplasty Patients
Scott Pascal¹, David Ayers², Wenjun Li², Leslie Harrold³, Jeroan Allison⁴ and Patricia D. Franklin², ¹University of Massachusetts Medical School, Worcester, MA, ²Orthopedics and Physical Rehabilitation, University of Massachusetts Medical School, Worcester, MA, ³Department of Orthopedics and Medicine, University of Massachusetts Medical School, Worcester, MA, ⁴Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA
Pre-Operative Musculoskeletal Comorbidities Limit Improvement In Functional Outcomes And Hip Pain In Total Hip Arthroplasty PatientsBackground/Purpose: Identifying clinical factors predictive of total hip arthroplasty…
Abstract Number: 1053 • 2014 ACR/ARHP Annual Meeting
Co-Morbidity Is Associated with Disease Severity in Early Rheumatoid Arthritis
Christopher Sparks¹, Aleena Abdullah², Steven Zhao³, Cristina Estrach³ and Nicola Goodson¹, ¹Musculoskeletal Biology1, University of Liverpool, Liverpool, United Kingdom, ²Musculoskeletal biology1, University of Liverpool, Liverpool, United Kingdom, ³Rheumatology, University Hospital Aintree, Liverpool, United Kingdom
Background/Purpose Co-morbidity has been shown to increase length of hospital stay and mortality in hospitalised patients. However, in early rheumatoid arthritis (eRA) co-morbidity may confound…
Abstract Number: 105 • 2014 ACR/ARHP Annual Meeting
Resource Use and Health Related Quality of Life Burden of Gout Exacerbated By Common Comorbidities: Results from the 2012-2013 National Health and Wellness Survey
Robert Morlock¹, Natalia M. Flores², Kathy Annunziata³, J. Chapnick⁴ and Sulabha Ramachandran⁵, ¹4939 Directors Place, Ardea Biosciences, San Diego, CA, ²Kantar Health, Foster City, CA, ³Kantar Health, Princeton, NJ, ⁴Kantar Health, Horsham, PA, ⁵AstraZeneca, Wilmington, DE
Background/Purpose: Gout is caused by chronic high serum uric acid (SUA) levels (i.e., hyperuricemia), which leads to the deposition of monosodium urate crystals in musculoskeletal…
Abstract Number: 1983 • 2013 ACR/ARHP Annual Meeting
Prevalence Of Birefringent Crystals In Three Inflammation-Prone Tissues
Jane Park¹, Divya Soman², Martine P. Roudier³ and Peter A. Simkin⁴, ¹Rheumatology, University of Washington, Seattle, WA, ²University of Washington, Seattle, WA, ³Pathology, University of Washington, Seattle, WA, ⁴Div of Rheumatology, University of Washington, Seattle, WA
Background/Purpose: When serum is hyperuricemic, so too are all interstitial fluids other than CSF and sweat. Anecdotally, urate crystals deposit as grossly visible tophi in…
Abstract Number: 1080 • 2013 ACR/ARHP Annual Meeting
Incidence Of Coronary Heart Disease Associated With Arthritis: A Canadian Population-Based Cohort Study
Orit Schieir¹, S. Hogg-Johnson², Richard H Glazier³ and Elizabeth M. Badley⁴, ¹Epidemiology, University of Toronto, Toronto, ON, Canada, ²Institute for Work and Health, Toronto, ON, Canada, ³nstitute for Clinical Evaluative Sciences, Sunnybrook Health Sciences Centre, Toronto, ON, Canada, ⁴Division of Health Care and Outcomes Research, Toronto Western Research Institute; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada
Background/Purpose: Several individual types of arthritis have been associated with increased coronary heart disease (CHD) morbidity in clinical studies, but whether arthritis overall increases the…
Abstract Number: 1019 • 2013 ACR/ARHP Annual Meeting
Comparison Of Comorbidity Indexes In a Clinical and Administrative Rheumatoid Arthritis Cohort: A Case For The Rheumatic Diseases Comorbidity Index
Bryant R. England¹, Harlan Sayles², Ted R. Mikuls², Dannette S. Johnson³ and Kaleb Michaud⁴, ¹Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ²Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ³Rheumatology, Jackson VA and University of Mississippi Medical Center, Jackson, MS, ⁴Rheumatology, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Quantifying comorbidities contribution to disability and mortality is important for assessing prognosis and standardizing cohorts in rheumatic disease research. A comorbidity index has been…
Abstract Number: 992 • 2013 ACR/ARHP Annual Meeting
Promise Of Behavioral Economics: Delay Discounting and Physical Activity In Patients With Musculoskeletal Diseases
Elena Losina¹, Yan Dong¹, Stephanie Chen², Ran Schwarzkopf³, Laurel Donnell-Fink⁴, David Lerner² and Jeffrey N. Katz⁵, ¹Orthopaedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, ²Orthopedics and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, ³Orthopedics, University of California Irvine Medical Center, Orange, CA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Rheumatology and Orthopedics, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Despite strong evidence that physical activity (PA) is associated with better quality of life, less pain and better functional status in persons with musculoskeletal…
Abstract Number: 2137 • 2013 ACR/ARHP Annual Meeting
Important Predictors Of Patient-Reported Outcomes After TKR and THR Are Not Included In Risk Models Based On Administrative Data
Patricia D. Franklin¹, Leslie R. Harrold², Wenjun Li¹, Jeroan Allison³, David Ayers¹ and Courtland Lewis⁴, ¹Orthopedics and Physical Rehabilitation, University of Massachusetts Medical School, Worcester, MA, ²University of Massachusetts Medical School, Worcester, MA, ³Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA, ⁴Hartford Hospital, Hartford, CT
Background/Purpose: Because total knee (TKR) and total hip (THR) replacement surgery is performed to relieve pain and improve physical function in patients with advanced arthritis,…
Abstract Number: 2137 • 2012 ACR/ARHP Annual Meeting
Contribution of Disease Activity, Joint Damage and Comorbidity to Impairment (SOFI) and Disability (HAQ) in Rheumatoid Arthritis Patients Over 20 Years
Meliha C. Kapetanovic¹, Elisabet Lindqvist², Jan-Åke Nilsson³, Pierre Geborek⁴, Tore Saxne⁵ and Kerstin Eberhardt⁶, ¹Dept of Clinical Sciences Lund, Section of Rheumatology, Lund University, Lund, Sweden, ²Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund University, Lund, Sweden, ³Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁴Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, ⁵Section of Rheumatology, Deparment of Clinical Sciences, Lund, Lund University, Lund, Sweden, ⁶Department of Clinical Sciences Lund, Section of Rheumatology, Skåne University Hospital, Lund University, Lund, Sweden, Lund, Sweden
Background/Purpose: To study the contribution of disease activity, joint damage and co-morbidity on development of impairment measured by signals of functional impairment (SOFI) and disability…
Abstract Number: 1855 • 2012 ACR/ARHP Annual Meeting
Prevalence of Potential Drug-Drug and Drug-Condition Interactions in Fibromyalgia Patients Newly-Initiating Pregabalin or Duloxetine
Stephen Johnston¹, Margarita Udall², Joseph C. Cappelleri³, Barbara H. Johnson⁴, George Shrady⁴ and Stuart L. Silverman⁵, ¹Truven Health Analytics, Bethesda, MD, ²Pfizer Inc., New York, NY, ³Pfizer Inc., Groton, CT, ⁴Truven Health Analytics, Washington, DC, ⁵Cedars-Sinai Medical Center, UCLA Center of Excellence, Los Angeles, CA
Background/Purpose: Drug-drug and drug-condition interactions (DDI/DCI) can present a significant challenge to the appropriate prescribing of drugs. The risk of DDI/DCI may be elevated in…
Abstract Number: 1814 • 2012 ACR/ARHP Annual Meeting
Comparing Clinical Characteristics and Comorbidities of Gout Patients Treated with Allopurinol or Febuxostat
Michael A. Becker¹, Xiangyang Ye², Kasem S. Akhras³, Rima H. Tawk⁴, Sudhir Unni², Jason Young² and Carl V. Asche⁵, ¹Medicine, University of Chicago, Chicago, IL, ²University of Utah College of Pharmacy, Salt Lake City, UT, ³Global Outcomes Research, Takeda Pharmaceuticals International, Inc., Deerfield, IL, ⁴Center for pharmacoeconomic Research, University of Illinois at Chicago, Chicago, IL, ⁵Center for Outcomes Research, University of Illinois College of Medicine at Peoria, Peoria, IL
Background/Purpose: Gout is a common acute and potentially progressive disease affecting approximately 8 million Americans. Hyperuricemia (serum urate levels [sUA] >6.8mg/dL) is a major pathogenic…
Abstract Number: 1225 • 2012 ACR/ARHP Annual Meeting
Self Reported Comorbidity Is Common in Early Inflammatory Arthritis and Associated with Poorer Function and Quality of Life and Greater Disease Activity: Results From the Canadian Early Arthritis Cohort
Carol A. Hitchon¹, Gilles Boire², Boulos Haraoui³, Edward Keystone⁴, Janet E. Pope⁵, Vivian P. Bykerk⁶ and Canadian Early Arthritis Cohort (CATCH) Investigators⁷, ¹University of Manitoba, Winnipeg, MB, Canada, ²Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ³Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada, ⁶Rheumatology, Hospital for Special Surgery, New York, NY, ⁷Toronto, Canada
Background/Purpose: Chronic comorbid medical conditions may contribute to poor outcomes in rheumatoid arthritis. The extent of comorbidity, in particular cardiovascular disease (CVD), may be related…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].